- Filament Health Corp. (FH) and Psyence Group (PSYG) announced the conclusion of a royalty-bearing, worldwide commercial licensing agreement
- The agreement grants Psyence the worldwide right to commercialize Filament’s natural psilocybin drug candidate, PEX010, for palliative care
- Dr. Neil Maresky, Chief Executive Officer of Psyence, sat down with Daniella Atkinson to discuss the partnership with Filament Health
- Psyence Group Inc is a science-led psychedelic platform
- Psyence Group Inc. (PSYG) opened trading at C$0.12
Filament Health Corp. (FH) and Psyence Group (PSYG) announced the conclusion of a royalty-bearing, worldwide commercial licensing agreement.
The agreement grants Psyence the worldwide right to commercialize Filament’s natural psilocybin drug candidate, PEX010 (25 mg), for palliative care.
Dr. Neil Maresky, Chief Executive Officer of Psyence, sat down with Daniella Atkinson to discuss the partnership with Filament Health.
“We are pleased to further develop our partnership with Filament Health, a leader in developing natural psychedelic drug candidates. Our ability to deliver these much-needed substances to patients worldwide is enhanced by Filament’s support.”
The licensing agreement with Filament grants Psyence exclusivity in the United Kingdom, the United States, and the European Union within palliative care. Filament will receive milestone payments of up to $3 million over the course of Psyence’s clinical development and marketing authorizations achieved by Psyence, as well as a percentage of future net sales in the low double digits.
Psyence Group Inc is a science-led psychedelic platform led by experts in neurology, neuroscience, and drug development. The company builds and operates federally licensed commercial psilocybin cultivation and production facilities.
Psyence Group Inc. (PSYG) opened trading at C$0.12.
